Genomics and the Immune Landscape of Osteosarcoma

Inferring tumour purity and stromal and immune cell admixture from expression data

Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

The cancer genome atlas pan-cancer analysis project

The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · see citing works

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041 · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

Li, B., Severson, E. A., Pignon, J., Zhao, H., Li, T., Novak, J. S. S., Jiang, P., Shen, H., Aster, J. C., Rodig, S. J., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,419 · see citing works

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · see citing works

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Bielack, S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.776 · Cited by 2,391 · see citing works

Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program

Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199 · see citing works

Regulation and Function of the PD-L1 Checkpoint

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,187 · see citing works

Cancer Immunotherapy

Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · see citing works

Absolute quantification of somatic DNA alterations in human cancer

Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,003 · see citing works

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · see citing works

<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368 · see citing works

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,325 · see citing works

Translational biology of osteosarcoma

Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294 · see citing works

Genomic and Functional Approaches to Understanding Cancer Aneuploidy

Taylor, A. M., Shih, J., Ha, G., Gao, G. F., Zhang, X., Berger, A. C., Schumacher, S. E., Wang, C., Hu, H., Liu, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.007 · Cited by 1,027 · see citing works

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005 · see citing works

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · see citing works

Tissue-specific mutation accumulation in human adult stem cells during life

Blokzijl, F., de Ligt, J., Jager, M., Sasselli, V., Roerink, S., Sasaki, N., Huch, M., Boymans, S., Kuijk, E., Prins, P., et al. (2016) · Nature · doi:10.1038/nature19768 · Cited by 935 · see citing works

Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934 · see citing works

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 909 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations

Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865 · see citing works

Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis

Holland, A. J., & Cleveland, D. W. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2718 · Cited by 859 · see citing works

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859 · see citing works

Circulating levels of IGF-1 directly regulate bone growth and density

Yakar, S., Rosen, C. J., Beamer, W. G., Ackert‐Bicknell, C. L., Wu, Y., Liu, J., Ooi, G. T., Setser, J., Frystyk, J., Boisclair, Y. R., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15463 · Cited by 845 · see citing works

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · see citing works

Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage

Yoshida, K., & Miki, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02195.x · Cited by 753 · see citing works

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752 · see citing works

Telomeres in cancer: tumour suppression and genome instability

Maciejowski, J., & de Lange, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.171 · Cited by 745 · see citing works

Circulating levels of IGF-1 directly regulate bone growth and density

Yakar, S., Rosen, C. J., Beamer, W. G., Ackert-Bicknell, C. L., Wu, Y., Liu, J.-L., Ooi, G. T., Setser, J., Frystyk, J., Boisclair, Y. R., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215463 · Cited by 739 · see citing works

Chromothripsis and Kataegis Induced by Telomere Crisis

Maciejowski, J., Li, Y., Bosco, N., Campbell, P. J., & de Lange, T. (2015) · Cell · doi:10.1016/j.cell.2015.11.054 · Cited by 675 · see citing works

DNA Damage and Repair Biomarkers of Immunotherapy Response

Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D’Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 652 · see citing works

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620 · see citing works

Nonsense-mediated mRNA decay (NMD) mechanisms

Brogna, S., & Wen, J. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1550 · Cited by 593 · see citing works

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalPreprint

Brown, S. D., Warren, R. M., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 589 · see citing works

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 581 · see citing works

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

Flynn, R. L., Cox, K. E., Jeitany, M., Wakimoto, H., Bryll, A. R., Ganem, N. J., Bersani, F., Pineda, J. R., Suvà, M. L., Benes, C. H., et al. (2015) · Science · doi:10.1126/science.1257216 · Cited by 504 · see citing works

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481 · see citing works

Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy

Gianferante, D. M., Mirabello, L. J., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 470 · see citing works

Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution

Dewhurst, S. M., McGranahan, N., Burrell, R. A., Rowan, A., Gronroos, E. C., Endesfelder, D., Joshi, T., Mouradov, D., Gibbs, P., Ward, R. L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0285 · Cited by 450 · see citing works

Genomic correlates of response to immune checkpoint blockade

Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448 · see citing works

Determinants and clinical implications of chromosomal instability in cancer

Sansregret, L., Vanhaesebroeck, B., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.198 · Cited by 396 · see citing works

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

Wilky, B. A., Trucco, M. M., Subhawong, T. K., Florou, V., Park, W., Kwon, D., Wieder, E., Kolonias, D. S., Rosenberg, A. E., Kerr, D. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30153-6 · Cited by 394 · see citing works

Osteogenic sarcoma with clinically detectable metastasis at initial presentation.

Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Applewhite, A., Sun, M., & LaQuaglia, M. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.449 · Cited by 389 · see citing works

Chromothripsis and cancer: causes and consequences of chromosome shattering

Forment, J. V., Kaidi, A., & Jackson, S. P. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3352 · Cited by 385 · see citing works

Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human diseasePreprint

Walkley, C. R., Qudsi, R. A., Sankaran, V. G., Perry, J. A., Gostissa, M., Roth, S. I., Rodda, S. J., Snay, E. R., Dunning, P. S., Fahey, F. H., et al. (2008) · Genes & Development · doi:10.1101/gad.1656808 · Cited by 373 · see citing works

Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography

Thompson, L. H. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2012.06.002 · Cited by 357 · see citing works

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N. S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9940 · Cited by 353 · see citing works

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267 · see citing works

Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma

Behjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., Farndon, S. J., Collord, G., Wedge, D. C., Martincorena, I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15936 · Cited by 261 · see citing works

Immuno-genomic landscape of osteosarcoma

Wu, C.-C., Beird, H. C., Andrew Livingston, J., Advani, S., Mitra, A., Cao, S., Reuben, A., Ingram, D., Wang, W.-L., Ju, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14646-w · Cited by 251 · see citing works

Molecular genetics of osteosarcoma

Rickel, K., Fang, F., & Tao, J. (2016) · Bone · doi:10.1016/j.bone.2016.10.017 · Cited by 244 · see citing works

Programmed Cell Death Ligand 1 Expression in Osteosarcoma

Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D. C., Schwab, J. H., Nielsen, G. P., Chebib, I. A., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 195 · see citing works

APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replicationPreprint

Seplyarskiy, V. B., Soldatov, R., Popadin, K. Y., Antonarakis, S. E., Bazykin, G. A., & Nikolaev, S. I. (2016) · Genome Research · doi:10.1101/gr.197046.115 · Cited by 179 · see citing works

A Central Role for mTOR Kinase in Homeostatic Proliferation Induced CD8+ T Cell Memory and Tumor Immunity

Li, Q., Rao, R. R., Araki, K., Pollizzi, K. N., Odunsi, K. O., Powell, J. D., & Shrikant, P. A. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.006 · Cited by 160 · see citing works

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Bai, J., Gao, Z., Li, X., Dong, L., Han, W., & Nie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22690 · Cited by 157 · see citing works

The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer

Huang, J., Wang, L., Cong, Z., Amoozgar, Z., Kiner, E., Xing, D., Oršulić, S., Matulonis, U. A., & Goldberg, M. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.083 · Cited by 152 · see citing works

Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations

Bousquet, M., Noirot, C., Accadbled, F., de Gauzy, J. S., Castex, M., Brousset, P., & Gomez‐Brouchet, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw009 · Cited by 143 · see citing works

TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study

Wunder, J. S., Gökgöz, N., Parkes, R. K., Bull, S. B., Eskandarian, S., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.074 · Cited by 140 · see citing works

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers

Ock, C.-Y., Hwang, J., Keam, B., Kim, S.-B., Shim, J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 135 · see citing works

Loss of Rb proteins causes genomic instability in the absence of mitogenic signalingPreprint

van Harn, T., Foijer, F., van Vugt, M. A. T. M., Banerjee, R., Yang, F., Oostra, A. B., Joenje, H., & Riele, H. T. (2010) · Genes & Development · doi:10.1101/gad.580710 · Cited by 124 · see citing works

Deficiency of nucleotide excision repair is associated with mutational signature observed in cancerPreprint

Jager, M., Blokzijl, F., Kuijk, E., Bertl, J., Vougioukalaki, M., Janssen, R., Besselink, N. J. M., Boymans, S., de Ligt, J., Pedersen, J. S., et al. (2019) · Genome Research · doi:10.1101/gr.246223.118 · Cited by 94 · see citing works

Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

Wargo, J. A., Cooper, Z. A., & Flaherty, K. T. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0477 · Cited by 93 · see citing works

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

Engert, F., Kovac, M. B., Baumhoer, D., Nathrath, M., & Fulda, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10720 · Cited by 87 · see citing works

Association of MutantTP53with Alternative Lengthening of Telomeres and Favorable Prognosis in Glioma

Chen, Y.-J., Hakin-Smith, V., Teo, M., Xinarianos, G., Jellinek, D. A., Carroll, T., McDowell, D., MacFarlane, M. R., Boet, R., Baguley, B. C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0910 · Cited by 80 · see citing works

p53 Loss Increases the Osteogenic Differentiation of Bone Marrow Stromal Cells

He, Y., de Castro, L. F., Shin, M. H., Dubois, W., Yang, H. H., Jiang, S., Mishra, P. J., Ren, L., Gou, H., Lal, A., et al. (2014) · Stem Cells · doi:10.1002/stem.1925 · Cited by 70 · see citing works

Detection and benchmarking of somatic mutations in cancer genomes using RNA-seq data

Coudray, A., Battenhouse, A. M., Bücher, P., & Iyer, V. R. (2018) · PeerJ · doi:10.7717/peerj.5362 · Cited by 67 · see citing works

Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1

Palmerini, E., Agostinelli, C., Picci, P., Pileri, S. A., Marafioti, T., Lollini, P., Scotlandi, K., Longhi, A., Benassi, M. S., & Ferrari, S. M. (2017) · Oncotarget · doi:10.18632/oncotarget.22912 · Cited by 64 · see citing works

Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways

Werner, H., Sarfstein, R., LeRoith, D., & Bruchim, I. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00159 · Cited by 59 · see citing works

Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy

Zhao, X., & Subramanian, S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.004 · Cited by 51 · see citing works

Patterns of structural variation in human cancerPreprint

Li, Y.-L., Roberts, N. D., Weischenfeldt, J., Wala, J., Shapira, O., Schumacher, S., Khurana, E., Korbel, J., Imieliński, M., Beroukhim, R., et al. (2017) · bioRxiv · doi:10.1101/181339 · Cited by 48 · see citing works

Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer

O’Brien, T. D., Jia, P., Xia, J., Saxena, U., Jin, H., Vuong, H., Kim, P., Wang, Q., Aryee, M. J., Mino-Kenudson, M. A., et al. (2015) · Methods · doi:10.1016/j.ymeth.2015.04.016 · Cited by 43 · see citing works

Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.

Burgess, M. A., Bolejack, V., Tine, B. A. V., Schuetze, S. M., Hu, J. S., D’Angelo, S. P., Attia, S., Priebat, D. A., Okuno, S. H., Riedel, R. F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11008 · Cited by 40 · see citing works

Profiling targetable immune checkpoints in osteosarcoma

McEachron, T. A., Triche, T. J., Sorenson, L., Parham, D. M., & Carpten, J. D. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1475873 · Cited by 39 · see citing works

Increased genome instability and oxidative DNA damage and their association with IGF-1 levels in patients with active acromegaly

Bayram, F., Bıtgen, N., Dönmez‐Altuntaş, H., Çakır, İ., Hamurcu, Z., Şahin, F., Şimşek, Y., & Başkol, G. (2013) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2013.12.002 · Cited by 37 · see citing works

The possible role of insulin-like growth factor-1 in osteosarcoma

Li, Y.-S., Liu, Q., He, H.-B., & Luo, W. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.08.008 · Cited by 35 · see citing works

Identification of differentially expressed genes in the development of osteosarcoma using RNA-seq

Yang, Y., Zhang, Y., Qu, X., Xia, J., Li, D., Li, X., Wang, Y., He, Z., Su, L., Zhou, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13554 · Cited by 17 · see citing works

Deficiency of nucleotide excision repair explains mutational signature observed in cancerPreprint

Jager, M., Blokzijl, F., Kuijk, E., Bertl, J., Vougioukalaki, M., Janssen, R., Besselink, N. J. M., Boymans, S., de Ligt, J., Pedersen, J. S., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/221168 · Cited by 5 · see citing works

Advancing therapy for osteosarcoma

Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876 · see citing works

Advances on immunotherapy for osteosarcoma

Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270 · see citing works

Ferroptosis‐related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma

Lei, T., Hu, Q., Lei, P., & Hu, Y. (2021) · Cancer Science · doi:10.1111/cas.15131 · Cited by 114 · see citing works

Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential

Yang, W., Tang, F., Tu, C., Hornicek, F. J., Duan, Z., & Min, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215887 · Cited by 107 · see citing works

Current Status and Prospects of Targeted Therapy for Osteosarcoma

Hu, Z., Wen, S., Huo, Z., Wang, Q., Zhao, J., Wang, Z., Chen, Y., Zhang, L., Zhou, F., Guo, Z., et al. (2022) · Cells · doi:10.3390/cells11213507 · Cited by 73 · see citing works

Black phosphorus quantum dots camouflaged with platelet-osteosarcoma hybrid membrane and doxorubicin for combined therapy of osteosarcoma

Xu, Y., Du, L., Han, B., Wang, Y., Fei, J., Xia, K., Zhai, Y., & Yu, Z. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02016-9 · Cited by 44 · see citing works

Novel diketopyrrolopyrrole NIR-II fluorophores and DDR inhibitors for in vivo chemo-photodynamic therapy of osteosarcoma

Cheng, X., Zhang, C., Shen, K., Liu, H., Bai, C., Ding, Q., Guan, M., Wu, J., Tian, Z., Chen, D., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.136929 · Cited by 39 · see citing works

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial

Tang, L., Niu, X., Wang, Z., Cai, Q., Tu, C., Fan, Z., & Yao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811687 · Cited by 21 · see citing works

Novel circular RNA circATRNL1 accelerates the osteosarcoma aerobic glycolysis through targeting miR-409-3p/LDHA

Zhang, Q., Wang, L., Cao, L., & Wei, T. (2021) · Bioengineered · doi:10.1080/21655979.2021.1985343 · Cited by 19 · see citing works

MicroRNA-376b-3p targets RGS1 mRNA to inhibit proliferation, metastasis, and apoptosis in osteosarcoma

Zhang, L., Yao, M., Ma, W., Jiang, Y., & Wang, W. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4949 · Cited by 19 · see citing works

Children's Oncology Group's 2023 blueprint for research: Bone tumors

Reed, D. R., Grohar, P. J., Rubin, E. M., Binitie, O. T., Krailo, M., Davis, J. L., DuBois, S. G., & Janeway, K. A. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30583 · Cited by 20 · see citing works

Comprehensive analysis of copper-metabolism-related genes about prognosis and immune microenvironment in osteosarcoma

Lin, Z., He, Y., Wu, Z., Yuan, Y., Li, X., & Luo, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-42053-w · Cited by 19 · see citing works

Prognostic and immunological significance of an M1 macrophage-related gene signature in osteosarcoma

Mao, X., Song, F., Jin, J., Zou, B., Dai, P., Sun, M., Xu, W., Wang, L., & Kang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202725 · Cited by 16 · see citing works

A Comprehensive Understanding of the Genomic Bone Tumor Landscape: A Multicenter Prospective Study

Xie, X., Bian, Y., Li, H., Yin, J., Tian, L., Jiang, R., Zeng, Z., Shi, X., Lei, Z., Hou, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.835004 · Cited by 15 · see citing works

Identification of B cell marker genes based on single-cell sequencing to establish a prognostic model and identify immune infiltration in osteosarcoma

Zhang, Z., Zhang, J., Duan, Y., Li, X., Pan, J., Wang, G., & Shen, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026701 · Cited by 16 · see citing works

Osteosarcoma subtypes based on platelet-related genes and tumor microenvironment characteristics

Shu, Y., Peng, J., Feng, Z., Hu, K., Li, T., Zhu, P., Cheng, T., & Liang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.941724 · Cited by 15 · see citing works

Prognostic biomarkers correlated with immune infiltration in non‐small cell lung cancer

Xu, F., Cui, W., Liu, C., Feng, F., Liu, R., Zhang, J., & Sun, C. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13501 · Cited by 14 · see citing works

Naringenin induces ferroptosis in osteosarcoma cells through the STAT3-MGST2 signaling pathway

Li, Y., & Bai, X. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100657 · Cited by 13 · see citing works

A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes

Tang, H., Liu, S., Luo, X., Sun, Y. H., Li, X., Luo, K., Liao, S., Li, F., Liang, J., Zhan, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1150588 · Cited by 12 · see citing works

Exploring the immune microenvironment of osteosarcoma through T cell exhaustion-associated gene expression: a study on prognosis prediction

Zhu, J., Yuan, J., Arya, S., Zhi, D., Liu, X., & Jia, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1265098 · Cited by 13 · see citing works

Harnessing multi‑omics to revolutionize understanding and management of osteosarcoma: A pathway to precision medicine (Review)

Chen, X., Tian, B., Wang, Y., Zheng, J., & Kang, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5533 · Cited by 14 · see citing works

Analysis and Historical Evolution of Paediatric Bone Tumours: The Importance of Early Diagnosis in the Detection of Childhood Skeletal Malignancies

Iacobellis, G., Leggio, A., Salzillo, C., Lucà, S., Ortega-Ruiz, R., & Marzullo, A. (2025) · Cancers · doi:10.3390/cancers17030451 · Cited by 10 · see citing works

CYFIP1 coordinate with RNMT to induce osteosarcoma cuproptosis via AURKAIP1 m7G modification

Lin, Z., Wu, Z., He, Y., Li, X., & Luo, W. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01127-3 · Cited by 10 · see citing works

Osteoimmunology in bone malignancies: a symphony with evil

Song, C., Tong, T., Dai, B., Zhu, Y., Chen, E., Zhang, M., & Zhang, W. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.09.001 · Cited by 9 · see citing works

Immunosurveillance shapes the emergence of neo-epitope landscapes of sarcomas, revealing prime targets for immunotherapy

Osei-Hwedieh, D. O., Sedlacek, A. L., Hernandez, L. M., Agyekum-Yamoah, A., Iyer, S. G., Weiss, K. R., & Binder, R. J. (2023) · JCI Insight · doi:10.1172/jci.insight.170324 · Cited by 9 · see citing works

Development and validation of apoptosis‐related signature and molecular subtype to improve prognosis prediction in osteosarcoma patients

Hong, J., Li, Q., Wang, X., Li, J., Ding, W., Hu, H., & He, L. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24501 · Cited by 9 · see citing works

Differential gene expression analysis for osteosarcoma lung metastases

Liu, F., Pang, X., Yu, Z., & Wang, K. (2021) · Cancer Biomarkers · doi:10.3233/cbm-210232 · Cited by 7 · see citing works

MFNG is an independent prognostic marker for osteosarcoma

Gao, Y., Luo, L., Qu, Y., & Zhou, Q. (2023) · European journal of medical research · doi:10.1186/s40001-023-01139-x · Cited by 7 · see citing works

Current Advances in the Science of Osteosarcoma

(2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6 · Cited by 7 · see citing works

Exploring Emerging Therapeutic Targets in Osteosarcoma by Revisiting the Immune and Cancer-Intrinsic Hallmarks of Cancer

Tarone, L., Iacoviello, A., Lorenzo, A. D., Verta, R., Cossu, C., Conti, L., Cavallo, F., & Riccardo, F. (2025) · Cancers · doi:10.3390/cancers17233846 · Cited by 8 · see citing works

Targeting RBM39 suppresses tumor growth and sensitizes osteosarcoma cells to cisplatin

Wang, J., Zheng, L., Chen, W., Zhang, X., Lv, D., Zeng, C., Zhang, C., Zhang, R., Kang, T., & Zhong, L. (2024) · Oncogene · doi:10.1038/s41388-024-03242-7 · Cited by 7 · see citing works

Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy—A New Standard of Care?

Cooke‐Barber, J., Brungardt, J. G., Sorger, M., Pressey, J. G., Turpin, B. K., Nagarajan, R., Szabo, S., Sorger, J. I., Johnson, N. D., & Dasgupta, R. A. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13097-z · Cited by 6 · see citing works

Osteosarcoma’s genetic landscape painted by genes’ mutations

Urban, W., Krzystańska, D., Piekarz, M., Nazar, J., & Jankowska, A. (2023) · Acta Biochimica Polonica · doi:10.18388/abp.2020_6869 · Cited by 5 · see citing works

Importance of CD8 Tex cell-associated gene signatures in the prognosis and immunology of osteosarcoma

Lu, Y., Cao, N., Zhao, M., Zhang, G., Zhang, Q., & Wang, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-60539-z · Cited by 5 · see citing works

Construction and Validation of an Autophagy-Related Prognostic Model for Osteosarcoma Patients

Hu, Q., Lei, T., Lei, P., & Hu, Y. (2021) · Journal of Oncology · doi:10.1155/2021/9943465 · Cited by 5 · see citing works

Osteosarcoma-Associated Immune Genes as Potential Immunotherapy and Prognosis Biomarkers

Yang, L., Long, Y., & Xiao, S. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10444-3 · Cited by 5 · see citing works

Construction of biodegradable benzobisthiazole-based conjugated polymers with pendant β-cyclodextrin for synergistic mild-temperature chemo-photothermal therapy

Lai, Q., Huang, S., Wu, Y., Hu, B., Chen, S., Zhang, K., Xu, Y., Zhang, X., Sun, G., & Ouyang, Y. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114102 · Cited by 4 · see citing works

Bibliometric analysis and visualisation of research hotspots and frontiers on omics in osteosarcoma

Wang, X., Cao, X., Dai, Z., & Dai, Z. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05898-w · Cited by 5 · see citing works

Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology

Simon, J., Reita, D., Guérin, É., Lhermitte, B., Weingertner, N., Lefèbvre, F., Karanian, M., Masliah‐Planchon, J., Lindner, V., Onéa, A., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13034-7 · Cited by 4 · see citing works

Cuproptosis related lncRNA signature as a prognostic and therapeutic biomarker in osteosarcoma immunity

Gao, Z., Chen, S., & Ye, W. (2025) · Scientific Reports · doi:10.1038/s41598-024-84024-9 · Cited by 4 · see citing works

PSAT1 inhibits ferroptosis in osteosarcoma cells by activating the Xct/GPX4 signaling axis

Wang, P., Xiao, J., Zeng, J., Yang, F., Lin, M., Tao, L., Liu, H., & Zhan, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-09568-w · Cited by 4 · see citing works

Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma

Manara, M. C., Bruzzese, F., Formentini, L., Landuzzi, L., Pazzaglia, L., Laginestra, M. A., Carrabotta, M., Roca, M. S., Iannelli, F., Grumetti, L., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03440-5 · Cited by 3 · see citing works

Development and validation of an oxidative stress‑related prognostic signature in osteosarcoma: A combination of molecular experiments and bioinformatics

Xie, B., Tan, S., Li, C., & Liang, J. (2023) · Oncology Letters · doi:10.3892/ol.2023.13865 · Cited by 3 · see citing works

The immune cell infiltration-associated molecular subtypes and gene signature predict prognosis for osteosarcoma patients

Liu, B., Liu, X., Wang, G., & Chen, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-55890-0 · Cited by 3 · see citing works

Transcriptome combined with single-cell data to construct a prognostic model for glycosylation-related genes in osteosarcoma

Ding, N., Li, J., Shi, S., Wang, J., Ding, Y., & Yang, Q. (2026) · Discover Oncology · doi:10.1007/s12672-026-04761-3 · Cited by 2 · see citing works

Single nucleotide mutation changes the capability of CCN3 in osteosarcoma cell invasion and differentiation

Yan, X., Yan, W., Fu, X., Xu, Y., Zhu, N., Qiu, C., Bu, M.-M., Shen, Y., & Chen, M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101485 · Cited by 2 · see citing works

Identification of telomere-related gene subtypes and prognostic signatures in osteosarcoma

Song, Z., Yu, W., & Yin, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1545913 · Cited by 1 · see citing works

Construction of an immune prediction model for osteosarcoma based on coagulation-related genes

Jiang, Y., Wang, X., Li, Y., Lu, S., Chen, C., Lin, L., Yang, Q., Wang, H., & Zhu, D. (2025) · Discover Oncology · doi:10.1007/s12672-025-03214-7 · Cited by 1 · see citing works

Advances in immunotherapy for osteosarcoma: a review of emerging treatment strategies

Poboży, K., Domański, P., Domańska-Poboża, J., Konarski, W., & Poboży, T. (2023) · Oncoreview · doi:10.24292/01.or.132100923 · Cited by 1 · see citing works

Metformin Sensitizes Osteosarcoma Cells to Chemotherapy Through IGF-1R/miR-610/FEN1 PathwayPreprint

Dong, S., Xiao, Y., Zhu, Z., Ma, X., Peng, Z., Kang, J., Xie, B., Wang, J., Li, Z., & Wang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-147084/v1 · Cited by 1 · see citing works

Identification of prognostic neutrophil extracellular traps-related genes subtypes predicts prognostic and immune microenvironment for osteosarcoma patientsPreprint

Yang, J., Yu, H. Q., Yang, L., Yang, J., Cheng, P., Gong, S., Ouyang, H., Zeng, N., Jiang, F., Peng, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2966881/v1

Construction of an immune prediction model for osteosarcoma based on coagulation-related genesPreprint

Jiang, Y., Wang, X., Li, Y., Lu, S., Chen, C., Lin, L., Yang, Q., Wang, H., & Zhu, D. (2023) · Research Square · doi:10.21203/rs.3.rs-3231272/v1

Additional file 2 of MFNG is an independent prognostic marker for osteosarcoma

Gao, Y., Luo, L., Qu, Y., & Zhou, Q. (2023) · Figshare · doi:10.6084/m9.figshare.23788295

Additional file 1 of MFNG is an independent prognostic marker for osteosarcoma

Gao, Y., Luo, L., Qu, Y., & Zhou, Q. (2023) · Figshare · doi:10.6084/m9.figshare.23788292

Additional file 4 of MFNG is an independent prognostic marker for osteosarcoma

Gao, Y., Luo, L., Qu, Y., & Zhou, Q. (2023) · Figshare · doi:10.6084/m9.figshare.23788301

Additional file 3 of MFNG is an independent prognostic marker for osteosarcoma

Gao, Y., Luo, L., Qu, Y., & Zhou, Q. (2023) · Figshare · doi:10.6084/m9.figshare.23788298

Additional file 1 of Black phosphorus quantum dots camouflaged with platelet-osteosarcoma hybrid membrane and doxorubicin for combined therapy of osteosarcoma

Xu, Y., Du, L., Han, B., Wang, Y., Fei, J., Xia, K., Zhai, Y., & Yu, Z. (2023) · Figshare · doi:10.6084/m9.figshare.23803040

Optimization of osteosarcoma sample processing for epigenetic analysis: A comparative evaluation of formalin-fixed, paraffin-embedded samples with and without decalcification versus fresh tissue

González-López, J., González‐Rojo, P., Berenguer-Rubio, A., Casaní-Galdón, S., García, D., Valera, M. S., Vidal, A., Huart, M. C., Rangel, A., de la Calva, C., et al. (2026) · Revista Española de Patología · doi:10.1016/j.patol.2026.100881

Research on Pediatric Oncology

Metts, J. L., Raikar, S. S., Patel, K., Armstrong, A. E., & Dhir, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-19175-5_26

The m6A reader HNRNPC drives osteosarcoma metastasis and cisplatin resistance by stabilizing MTDH to coordinately regulate EMT and ferroptosis

Zhang, L., Zhou, Y., Yan, S., Zhang, X., Xu, T., Wang, X., Zhang, X., An, W., Xing, Y., & Song, Y. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026179

Comprehensive genomic landscape of osteosarcoma: Systematic review and analysis of 1,058 patients across 20 studies with therapeutic implications from the Fight Osteosarcoma Through European Research (FOSTER) Consortium.

Palmerini, E., Bertrand, M., McFarlane, E., Cullinan, N. M., Gambarotti, M., Entz‐Werlé, N., Frega, G., Winter, S., Marchais, A., & McCabe, M. G. (2026) · Journal of Clinical Oncology · doi:10.1200/jco.2026.44.16_suppl.10032 · Cited by 1 · see citing works

Analysis of the Mutational Landscape of Osteosarcomas Identifies Genes Related to Metastasis and Prognosis and Disrupted Biological Pathways of Immune Response and Bone Development

Pires, S. F., de Barros, J. S., da Costa, S. S., do Carmo, G. B., Scliar, M. O., Lengert, A. V. H., Boldrini, É., da Silva, S. R. M., Vidal, D. O., Maschietto, M. C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310463 · Cited by 16 · see citing works

Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.

Livingston, J. A., Beird, H. C., Wu, C.-C., Cao, S., Advani, S., Ingram, D. R., Wang, W., Lazar, A. J., Leung, C. H., Lin, H. Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.10520

Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics

Yang, C., Yu, Y., Wang, Y., Cai, Z., Zhao, Y., Ma, H., Xu, J., Zhu, H., Ren, T., Tang, X., et al. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101930

Deciphering osteosarcoma development and evolution using whole genome and single cell technologies

Noon, S. D. (2025) · UCL Discovery (University College London)